Works matching IS 11753277 AND DT 2025 AND VI 25 AND IP 1

Results: 14

Flurpiridaz F 18: First Approval: Flurpiridaz F 18: First Approval: S. J. Keam.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 1, doi. 10.1007/s40256-024-00718-5

By:

Keam, Susan J.

Publication type:

Article

Bempedoic Acid: A Review in Cardiovascular Risk Reduction in Statin-Intolerant Patients: Bempedoic Acid: A Review: A. McGuigan, H. A. Blair.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 7, doi. 10.1007/s40256-024-00714-9

By:

McGuigan, Aisling;
Blair, Hannah A.

Publication type:

Article

Author's Reply to Peronard and Mayntz: "SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect": Author's Reply to Peronard and Mayntz: D. Aristizábal-Colorado et al.

Published in:

2025

By:

Aristizábal-Colorado, David;
Ocampo-Posada, Martín;
Rivera-Martínez, Wilfredo Antonio;
Corredor-Rengifo, David;
Rico-Fontalvo, Jorge;
Gómez-Mesa, Juan Esteban;
Duque-Ossman, John Jairo;
Abreu-Lomba, Alin

Publication type:

Letter

Comment on "SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect": Comment on "SGLT2 Inhibitors: R. Peronard and S. Mayntz.

Published in:

2025

By:

Peronard, Rose;
Mayntz, Stephan

Publication type:

Letter to the Editor

Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis: Cardiovascular Safety of Patisiran: V. Jaiswal et al.

Published in:

2025

By:

Jaiswal, Vikash;
Kalra, Kriti;
Deb, Novonil;
Mattumpuram, Jishanth

Publication type:

Letter

Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor Used in the Management of Pulmonary Arterial Hypertension: Sotatercept in PAH: J. Villanueva et al.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 17, doi. 10.1007/s40256-024-00694-w

By:

Villanueva, Josiah;
Wade, Jasmine;
Torres, Ana;
Hale, Genevieve;
Pham, Huy

Publication type:

Article

Efficacy of Colchicine for Prevention of Stroke and Adverse Cardiovascular Events: A Meta-analysis of 16 Randomized Controlled Trials: Efficacy of Colchicine for Prevention of Stroke and Adverse CV Events: A Meta-analysis of RCTs: V. Jaiswal et al.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 83, doi. 10.1007/s40256-024-00689-7

By:

Jaiswal, Vikash;
Deb, Novonil;
Hanif, Muhammad;
Wajid, Zarghoona;
Nasir, Yusra Minahil;
Naz, Sidra;
Kalra, Kriti;
Qaiser, Saria;
Shrestha, Abhigan Babu;
Bandyopadhyay, Dhrubajyoti;
Mattumpuram, Jishanth

Publication type:

Article

Vitamin D–Parathyroid Hormone–Fibroblast Growth Factor 23 Axis and Cardiac Remodeling: Vitamin D–Parathyroid Hormone–FGF23 Axis and Cardiac Remodeling: C. Deng et al.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 25, doi. 10.1007/s40256-024-00688-8

By:

Deng, Cuiyun;
Wu, Yihang

Publication type:

Article

Cardiomodulatory Effects of Cardiometabolic and Antihyperglycemic Medications: The Roles of Oxidative and Endoplasmic Reticulum Stress: Cardioprotective Effects of Antihyperglycemic Medications: A. D. Mooradian.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 37, doi. 10.1007/s40256-024-00685-x

By:

Mooradian, Arshag D.

Publication type:

Article

Efficacy of Chronic Use of Sodium–Glucose Co-transporter 2 Inhibitors on the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Type 2 Diabetes Mellitus Following Coronary Procedures: A Systematic Review and Meta-Analysis: SGLT2 Inhibitors and Contrast-Induced AKI: K. Dimitriadis et al

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 57, doi. 10.1007/s40256-024-00684-y

By:

Dimitriadis, Kyriakos;
Vakka, Angeliki;
Pyrpyris, Nikolaos;
Apostolos, Anastasios;
Beneki, Eirini;
Stathopoulou, Elpiniki;
Giannou, Panagiota;
Tsioufis, Panagiotis;
Iliakis, Panagiotis;
Aznaouridis, Konstantinos;
Petras, Dimitrios;
Tsioufis, Konstantinos

Publication type:

Article

Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients with Heterozygous Familial Hypercholesterolemia: A Meta-analysis: PCSK9 Inhibitors in Heterozygous FH: M. Movahedan et al.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 47, doi. 10.1007/s40256-024-00682-0

By:

Movahedan, Mahsa;
Ellis, Ursula M.;
Barry, Arden R.

Publication type:

Article

Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: SGLT2i Post-AMI: N. H. Y. Lin et al.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 71, doi. 10.1007/s40256-024-00680-2

By:

Lin, Norman H Y;
Ho, Jamie S. Y.;
Leow, Aloysius S. T.;
Teo, Yao Hao;
Yeo, Brian S. Y.;
Zhang, Audrey A. Y.;
Goh, Fang Qin;
Yeo, Tiong-Cheng;
Wong, Raymond C. C.;
Chai, Ping;
Chan, Mark Y. Y.;
Sia, Ching-Hui

Publication type:

Article

Long-Term Effects of Low-Dose Aspirin on Gastrointestinal Symptoms and Bleeding Complications in Patients with Type 2 Diabetes: Long-Term Effects of Low-Dose Aspirin on Gastrointestinal Symptoms and Bleeding: N. Masutani et al.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 95, doi. 10.1007/s40256-024-00679-9

By:

Masutani, Naoko;
Ogawa, Hisao;
Soejima, Hirofumi;
Okada, Sadanori;
Masuda, Izuru;
Waki, Masako;
Jinnouchi, Hideaki;
Saito, Yoshihiko;
Morimoto, Takeshi

Publication type:

Article

The Influence of High Body Mass Index (BMI > 35 kg/m<sup>2</sup>) on Apixaban Plasma Concentration in Patients with Atrial Fibrillation: BMI ≥ 35 kg/m<sup>2</sup> Impact on Apixaban Levels in Atrial Fibrillation Patients: M. Hilu et al.

Published in:

American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 113, doi. 10.1007/s40256-024-00678-w

By:

Hilu, May;
Issawy, Mariana;
Colodner, Raul;
Eitam, Harel;
Avraham, Gilat Ron;
Ram, Kerstin Carlin;
Elias, Mazen;
Shimoni, Orli;
Schwartzberg, Eyal;
Goldstein, Lee Hilary

Publication type:

Article